In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomics Through The Lens Of Precompetitive Data Sharing

Executive Summary

With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.

Advertisement

Related Content

Making The Most Of A Maturing Myriad Genetics
Genomics Enters The Neonatal ICU
Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF
Diagnostic Industry Trends Hinge On Gene-Based Tests
Trends In Diagnostics 2011
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Delivering Cancer Diagnostics Tools
The How And When Of Applying Sequencing To Clinical Diagnostics
Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel